Compare Charles River Laboratories Intl. Inc (CRL) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs Wolfspeed Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $286.53 (market cap $13.46B), while Wolfspeed Inc trades at $32.08 (market cap $1.57B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 8.6× Wolfspeed Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| CRL | WOLF | |
|---|---|---|
Market Cap | $13.46B | $1.57B |
Sector | Health | Technology |
52-Week High | $282.00 | $73.68 |
52-Week Low | $145.57 | $1.19 |
Enterprise Value | $16.30B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
WOLF is trading at $32.24, up 10.03% today, showing strong momentum amid a bullish technical outlook. The stock faces fundamental challenges with negative gross (-26.63%) and net (-79.83%) margins, though recent earnings beat expectations in two of the last three quarters. Positive developments include strategic partnerships with LITEON and GE Aerospace for silicon carbide technology in AI data centers and defense applications, driving investor optimism despite profitability concerns.
The outlook is mixed: technical strength and AI/defense partnerships offer upside, but persistent losses and competitive risks warrant caution. Analysts are divided (31.58% Buy, 47.37% Hold), highlighting the stock's high-risk, high-reward profile. Key risks include execution on profitability, patent litigation with Navitas, and reliance on emerging tech adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
